SnapDNA key facts
as of Oct 2026- Developer of on-site pathogen testing technology designed to create a rapid pathogen detection system for food processing facilities.
- SnapDNA is valued at approximately $28.0M as of Oct 2026 (last reported valuation).
- It has raised $4.8M; the latest was Angel (individual) ($500K) in Mar 2025.
- Notable investors include Plug and Play Tech Center, In-Q-Tel, Aria Emiko (Investment), Accel Impact Ventures, Advanced Industries Accelerator — 7 tracked in total.
- Status: Privately Held (backing).
SnapDNA's last reported valuation, Apr 2021. Nothing priced has surfaced since.
- ·Watch SnapDNA: the Monday email on marks, rounds and moves
SnapDNA funding rounds
No funding rounds for SnapDNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
SnapDNA valuation
SnapDNA's last reported valuation was $28 million in Apr 2021. No priced round, secondary trade or fund mark has surfaced since.
SnapDNA investors
7 investors are on record for SnapDNA, including Plug and Play Tech Center, In-Q-Tel, Aria Emiko (Investment) and Accel Impact Ventures.
About SnapDNA
Developer of on-site pathogen testing technology designed to create a rapid pathogen detection system for food processing facilities. The company's analysis eliminates the time taking procedure of food pathogen testing and reduces the number and severity of outbreaks of pathogens, enabling clients to lower production costs and offer fresh and safe food.
- Sector
- Healthcare
- HQ
- Broomfield, CO, United States
- Founded
- 2011
- Employees
- 7
- Website
- snapdna.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.